ライフサイエンスコーパス: glipizide

1 h, and steeper slope to glucose trough after glipizide.

2 seen with the sulfonylureas tolbutamide and glipizide.

3 n sulfonylureas: glimepiride, glyburide, and glipizide.

4 ) insulin three to four times daily, with no glipizide.

5 D, the risk of MACE-4 events was highest for glipizide.

6 limepiride, and 9.1% (95% CI, 8.7%-9.7%) for glipizide.

7 o of MACE-4 was 1.13 (95% CI, 1.03-1.23) for glipizide, 1.07 (95% CI, 0.96-1.16) for glimepiride, and

8 ol, 89 mg/dL [70-112 mg/dL]), 18 147 started glipizide, 14 282 started glimepiride, 1887 started glyb

9 om long-acting to short-acting sulfonylurea (glipizide), (3) discontinuation of sulfonylurea, or (4)

10 long-acting insulin; 2) addition of daytime glipizide; 3) insulin twice daily, with no glipizide; an

11 The sulfonylurea glipizide (50 microM) produced a transient 25% increase

12 Using the TRAMP transgenic mouse model, glipizide, a widely used drug for type 2 diabetes mellit

13 glyburide (aHR, 1.26 [CI, 1.16 to 1.37]) and glipizide (aHR, 1.15 [CI, 1.06 to 1.26]) in subgroups by

14 effects of the water-soluble sodium salt of glipizide, an inhibitor of ATP-sensitive potassium chann

15 itoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride)

16 e glipizide; 3) insulin twice daily, with no glipizide; and 4) insulin three to four times daily, wit

17 d escitalopram), and insulin initiation (for glipizide) between the groups.

18 diet and titration with either 5 to 20 mg of glipizide gastrointestinal therapeutic system (GITS) (n

19 jects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic system (GITS).

20 creased in the glyburide group compared with glipizide GITS in the 20-mg study (P=.05).

21 Favorable health economic outcomes for glipizide GITS included higher retained employment (97%

22 , 5.8 mmol/L [105 mg/dL] for a 20-mg dose of glipizide GITS vs 8.7 mmol/L [157 mg/dL] for placebo), a

23 lucose levels decreased with active therapy (glipizide GITS) vs placebo (7.5% 0.1% vs 9.3%+/-0.1% and

24 ken together, these results demonstrate that glipizide has the potential to be repurposed as an effec

25 etics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH), we constructed weighted

26 These findings suggest that sulfonylureas, glipizide in particular, may not be the optimal agent in

27 t by N(omega)-nitro-L-arginine methyl ester, glipizide, indomethacin or 17-octadecynoic acid.

28 Moreover, glipizide inhibits the tubular structure formation of hu

29 domly assigned to groups treated with either glipizide or insulin at doses appropriate to control hyp

30 treatment with a sulfonylurea (glimepiride, glipizide, or glyburide) or a DPP4i (reference category)

31 omes were noted for alendronate, calcitonin, glipizide, or quinapril.

32 Intriguingly, glipizide significantly reduces microvessel density in P

33 However, the higher doses of glipizide sodium salt attenuated the increments in plasm

34 renteral administration of the water-soluble glipizide sodium salt attenuates vascular and end-organ

35 subjected to pressure-controlled hemorrhage, glipizide sodium salt improved mean arterial pressure in

36 ntramuscular (10 and 40 mg/kg) injections of glipizide sodium salt or vehicle.

37 In addition, the glipizide treated cats had threefold higher basal and fi

38 At the end of the study all 4 glipizide-treated cats had islet amyloid deposits, where

39 glipizide) were on opposite sides of and could not exclu

40 nt 6-month combination therapy of metformin, glipizide XL, and acarbose to lower A1C to 6.7% and 2-da